,0
symbol,IGMS
price,54.09
beta,0.0
volAvg,202766
mktCap,1660595460
lastDiv,0.0
range,19.43-89.81
changes,0.73
companyName,IGM Biosciences Inc
currency,USD
cik,0001496323
isin,US4495851085
cusip,449585108
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://igmbio.com/
description,"IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 54 full-time employees. The company has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Companyâ€™s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The firm is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR)."
ceo,Mr. Fred Schwarzer
sector,Healthcare
country,US
fullTimeEmployees,77
phone,16509657873
address,325 E Middlefield Rd
city,Mountain View
state,CALIFORNIA
zip,94043
dcfDiff,
dcf,64.3999
image,https://financialmodelingprep.com/image-stock/IGMS.jpg
ipoDate,2019-09-18
defaultImage,True
